Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to quiet inflamed arteries in heart patients

NCT ID NCT06263244

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This study tests whether ziltivekimab, an anti-inflammatory drug, can reduce inflammation in the artery walls of people with heart disease. About 40 adults aged 50 and older with multiple blocked arteries and high inflammation levels will receive either the drug or a placebo. Researchers will use advanced imaging and blood tests to measure changes in inflammation over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam UMC, location AMC

    RECRUITING

    Amsterdam, 1105AZ, Netherlands

Conditions

Explore the condition pages connected to this study.